Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Trial Number
NCT02354131 (ClinicalTrials.gov Identifier)Contact Person
Status
Completed
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
GOG-F